Venn Life Sciences (AIM: VENN) have had a strong first half of 2015 with the Company billing in excess of EUR4m, up 170% against the same period in 2014 (H1: EUR1.5m).
The Company has demonstrated continued growth throughout 2015 driven by contract wins amounting to over EUR9m in the period to 30 June 2015.
Commenting on the figures, Venn CEO, Tony Richardson said: “Our fee income figures highlight the steady and consistent growth of the Company year on year with both repeat business and organic growth contributing to our excellent results and ability to win projects internationally. Our market continues to grow steadily and with a healthy pipeline of prospects we are well positioned to deliver further growth.”
